CN104080449A - 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法 - Google Patents

4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法 Download PDF

Info

Publication number
CN104080449A
CN104080449A CN201280066774.3A CN201280066774A CN104080449A CN 104080449 A CN104080449 A CN 104080449A CN 201280066774 A CN201280066774 A CN 201280066774A CN 104080449 A CN104080449 A CN 104080449A
Authority
CN
China
Prior art keywords
peg
cancer
fatty acid
acid ester
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280066774.3A
Other languages
English (en)
Chinese (zh)
Inventor
蒋志伟
李弦
徐海蓉
叶燕
胡红伟
杨欢欢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd
Original Assignee
Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd filed Critical Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd
Publication of CN104080449A publication Critical patent/CN104080449A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201280066774.3A 2012-02-17 2012-02-17 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法 Pending CN104080449A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/000190 WO2013120229A1 (en) 2012-02-17 2012-02-17 METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS

Publications (1)

Publication Number Publication Date
CN104080449A true CN104080449A (zh) 2014-10-01

Family

ID=48983518

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280066774.3A Pending CN104080449A (zh) 2012-02-17 2012-02-17 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法

Country Status (5)

Country Link
US (1) US20150164794A1 (cg-RX-API-DMAC7.html)
EP (1) EP2814480A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015506990A (cg-RX-API-DMAC7.html)
CN (1) CN104080449A (cg-RX-API-DMAC7.html)
WO (1) WO2013120229A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107660202A (zh) * 2015-03-27 2018-02-02 美国波士顿生物技术公司 水溶性前药

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2951627A1 (en) 2014-06-09 2015-12-17 Kyoto Pharmaceutical Industries, Ltd. Naphthofuran derivatives as anticancer agent
JP6810036B2 (ja) 2015-07-17 2021-01-06 大日本住友製薬株式会社 ２−アセチル−４Ｈ，９Ｈ−ナフト［２，３−ｂ］フラン−４，９−ジオンの製造方法
EP3686182A4 (en) 2017-09-22 2021-06-09 Sumitomo Dainippon Pharma Co., Ltd. CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101854937A (zh) * 2007-09-10 2010-10-06 波士顿生物医药公司 新的stat3途径抑制剂和癌症干细胞抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04139177A (ja) * 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2012119265A1 (en) * 2011-03-04 2012-09-13 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101854937A (zh) * 2007-09-10 2010-10-06 波士顿生物医药公司 新的stat3途径抑制剂和癌症干细胞抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TAKANO, AYAKO ET AL.: "Tumor-specific cytotoxicity and type of cell death induced by naphtho[2,3-b]furan-4,9-diones and related compounds in human tumor cell lines: relationship to electronic structure", 《 ANTICANCER RESEARCH》 *
奉建芳: "我国纳米给药系统的研究与应用", 《中南药学》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107660202A (zh) * 2015-03-27 2018-02-02 美国波士顿生物技术公司 水溶性前药
US10800752B2 (en) 2015-03-27 2020-10-13 Boston Biomedical, Inc. Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer
CN107660202B (zh) * 2015-03-27 2021-12-24 大日本住友制药肿瘤公司 水溶性前药
US11414394B2 (en) 2015-03-27 2022-08-16 Sumitomo Pharma Oncology, Inc. Process for producing a hydrate of a hydrochloride salt of 2,2′-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid

Also Published As

Publication number Publication date
WO2013120229A1 (en) 2013-08-22
EP2814480A1 (en) 2014-12-24
US20150164794A1 (en) 2015-06-18
JP2015506990A (ja) 2015-03-05
EP2814480A4 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
CA2946899C (en) Naphthofuran compounds and compositions for targeting cancer stem cells
JP6433085B2 (ja) がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
JP2014511384A (ja) 疾患治療のための４，９−ジヒドロキシ−ナフト［２，３−ｂ］フランの新規エステル
US20160038454A1 (en) Intravenous formulations of triptolide compounds as immunomodulators and anticancer agents
CA2946890A1 (en) Naphthofuran compounds and compositions for targeting cancer stem cells
JP2021147340A (ja) 化合物、そのナノ粒子及び癌疾患の治療剤
JP2020063308A (ja) がん幹細胞を標的とするための新規の化合物および組成物
CN112245591A (zh) 化疗药物-低氧激活前药一体化前药自组装纳米粒的构建
US20200384007A1 (en) Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof
JP2021521222A (ja) ６，８−ビス−ベンジルチオ−オクタン酸を使用して前立腺癌を治療するための治療方法および組成物
CN104080449A (zh) 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法
DK2528598T3 (en) RELATIONS TO suppress PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT
CN112654626A (zh) 化合物及其用途
CN103965175B (zh) 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用
CA3017557A1 (en) Combination therapy for proliferative diseases
CN111803489A (zh) 含笑内酯及其衍生物在垂体腺瘤治疗中的应用
WO2019146130A1 (ja) 胆道がん用抗腫瘍剤および胆道がんの処置方法
CN101830819B (zh) 苯丁酰基姜黄素衍生物及其在制备抗肿瘤药物中的应用
CN1743337B (zh) 一种紫杉醇衍生物及其药物组合物
US20070286906A1 (en) Dihydrobenzoquinone compounds
KR20210141214A (ko) 3원환 화합물 및 이의 의약 용도
JPH11217338A (ja) キノリン誘導体を用いる医薬品の効果改善および増強剤
CN113491680A (zh) 邻苯二酚及衍生物在制备用于治疗睡眠障碍药物中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: HANGZHOU YIER BIOTECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD.

Effective date: 20150906

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150906

Address after: 310018, building 2, building 452, No. 6, Avenue, Hangzhou economic and Technological Development Zone, Zhejiang, Hangzhou

Applicant after: Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd.

Address before: 316021 No. 112, Yi Dao Road, Xincheng, Zhejiang, Zhoushan

Applicant before: Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141001